I’m updating our chelonian and squamate pain protocols and want to make sure we aren’t under-treating or risking renal blowback. For bearded dragons I’ve seen meloxicam at [redacted]/kg PO and I’m trialing gabapentin in tegus — what current papers, formularies, or CE notes (post-2020) are you leaning on? Species-specific guidance keeps these patients safer, so any vetted resources would help me tighten our sheet this week.